Neoadjuvant, Adjuvant, and Perioperative Options in NSCLC
Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss personalized treatment approaches for non-small cell lung cancer tailored to individual patient needs and goals.
This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.
Forde and Cascone discuss the increasing treatment options for early-stage and locally advanced resectable non–small cell lung cancer (NSCLC), including neoadjuvant, perioperative, and adjuvant therapies. The decision to pursue surgery first or neoadjuvant therapy is made through multidisciplinary tumor boards or clinics, considering anatomical and functional factors as well as patient needs.
In many cases, neoadjuvant chemoimmunotherapy is provided, and resectability is reassessed after treatment, as events during the neoadjuvant phase may impact a patient’s suitability for surgery. If a patient is deemed unresectable upfront for robust reasons, such as the presence of multistation N2 disease, chemoradiation followed by consolidation therapy may be considered for local control.
Patient goals and the ability to tolerate a year of postsurgical therapy are also important considerations when tailoring treatment approaches. The rapid evolution in managing these patients has led to more patients being considered for surgery who may have been previously directed to chemoradiation. Close collaboration among the surgeon, radiation oncologist, and medical oncologist is crucial in making these treatment decisions.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
